Skip to main content

ORIGINAL RESEARCH article

Front. Neurol.
Sec. Headache and Neurogenic Pain
Volume 15 - 2024 | doi: 10.3389/fneur.2024.1459767

Efficacy of onabotulinumtoxinA Treatment in Episodic Migraine

Provisionally accepted
Jasem Yousef Al-Hashel Jasem Yousef Al-Hashel 1,2*Raed Alroughani Raed Alroughani 3Malak Almojel Malak Almojel 4Samar Farouk Ahmed Samar Farouk Ahmed 2
  • 1 Health Science Center, Kuwait, Kuwait, Kuwait
  • 2 Ibn Sina Hospital, Kuwait City, Kuwait
  • 3 Division of Neurology, Amiri Hospital, Kuwait, Kuwait
  • 4 Amiri Hospital, Kuwait City, Kuwait

The final, formatted version of the article will be published soon.

    Background: OnabotulinumtoxinA (BoNT-A) is approved as a prophylactic treatment of chronic migraine (CM) only. We aimed to assess the efficacy and safety of BoNT-A in the treatment of episodic migraine (EM). Methods: This is a prospective study included migraine patients, aged 18 -65 years, and completed one year treatment with BoNT-A. Patients received 4 courses of BoNT-A treatment. Patient's headache was assessed by headache diary at baseline, and before every injection. Migraine Specific Quality of Life Questionnaire (MSQ) and work productivity were collected at baseline and in their last visit. Adverse events (AEs) were reported. Results: The study recruited 210 patients. Between baseline and the final visit, there were a significant reduction in migraine days, analgesic consumption days, and headache severity (9.54 +1.70 versus 4.58+ 2.77, P < 0.001), (8.47 +1.49 versus 2.98+ 0.21, P < 0.001), (8.37+ 0.72versus 2.54 +0.18, P < 0.001), respectively. BoNT-A treatment reduced the mean number of missed hours from work and daily activities over a 7-day period (4.63 +2.39 versus 6.26 +2.04, P < 0.001); (2.24+ 3.30 versus 3.94 +3. 45; P < 0.001).

    Keywords: episodic migraine, Botulinum Toxin-A, Migraine-Specific Quality of Life, Productivity and Activity Impairment, Headache, Migraine-Specific Quality of Lif, Productivity and Activity Impairment

    Received: 04 Jul 2024; Accepted: 28 Oct 2024.

    Copyright: © 2024 Al-Hashel, Alroughani, Almojel and Ahmed. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Jasem Yousef Al-Hashel, Health Science Center, Kuwait, Kuwait, Kuwait

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.